Available Screening Programs for the Early Identification of Cancers: A Targeted Literature Review
Author(s)
Aguiar-Ibáñez R1, Sharma S2, Tomassy J3, Puppala M4, Aktan G5
1Merck Canada Inc., Toronto, ON, Canada, 2Parexel International, Mohali, India, 3PAREXEL International, Cracow, Poland, 4Parexel International, Bangalore, India, 5Merck & Co., Inc., Rahway, NJ, USA
Presentation Documents
OBJECTIVES:
Screening for cancers can help to reduce the incidence of invasive cancers and subsequent mortality. This study aimed to understand the landscape of currently recommended screening programs (criteria for screening, recommended frequency and uptake) for the early identification of cancer across the following countries: France, Germany, Italy, Spain, UK, US, Canada, Mexico, Argentina, Brazil, Australia and Japan.METHODS:
A targeted literature review was conducted on MEDLINE® and other publicly available sources (up to November 2022) to summarize currently recommended screening programs for early detection of cancer.RESULTS:
All included countries had population-based screening programs for breast, cervical and colorectal cancers except for Mexico and Argentina. Lung cancer screening was recommended only in high-risk (smoker) populations in Germany, UK, US, Australia and Japan. Population-based screening programs for melanoma and prostate cancer were only recommended in Germany, and gastric cancer screening was only identified in Japan. No population-based screening programs were identified for endometrial, ovarian, pancreatic, renal, or bladder cancer. Germany targeted the highest number of cancer types (n=6) through screening programs, followed by Japan (n=5), then the UK, Australia, and US (n=4 for each). In the remaining countries, no screening programs aside from those for breast, cervical and colorectal cancers were identified. In most countries, the screening programs were limited to patient populations up to 75 years of age. Screening was typically recommended in patients over 45–50 years of age, apart from cervical cancer where screening was recommended from the age of 20–25 years onwards.CONCLUSIONS:
While population-based screening programs have been consistently implemented across countries to identify patients with breast, cervical and colorectal cancers (who represent a large proportion of new cases), the implementation for screening programs for other tumour types have been limited and in some cases (e.g. lung cancer) restricted to high risk populations.Conference/Value in Health Info
2023-05, ISPOR 2023, Boston, MA, USA
Value in Health, Volume 26, Issue 6, S2 (June 2023)
Code
EPH136
Topic
Study Approaches
Topic Subcategory
Literature Review & Synthesis
Disease
No Additional Disease & Conditions/Specialized Treatment Areas